洋医汇 Generic drug intelligence
Information resource for healthcare professionals and licensed importers. Not medical advice. No direct-to-consumer sales of prescription medicines.
Bangladesh · regulated by DGDA

Crizotinib price in Bangladesh (2026)

Bangladesh list prices converted into BDT, plus the registration rules of the DGDA, the legal import routes and the real cost build-up for Bangladesh.

Quick answer: crizotinib price in Bangladesh

Bangladeshi list price for generic crizotinib250 mg is BDT 350–BDT 1,500 per unit (about BDT 350–BDT 1,500), i.e. BDT 10,500–BDT 45,000 per 30-unit month; add freight, duty and distributor margin for $Bangladesh.

FX basis: 1 USD = 122.87 BDT (September 2026). Conversions are indicative only — the binding price is your supplier quotation.

Currency conversion

ItemBDTBDTUSD
Lowest unit price BDT 350 BDT 350 US$2.85
Highest unit price BDT 1,500 BDT 1,500 US$12.21
30-unit month (lowest) BDT 10,500 BDT 10,500 US$85.46
30-unit month (highest) BDT 45,000 BDT 45,000 US$366.24

Bangladesh benchmark (world reference price)

Registered brands and list prices for this molecule in Bangladesh (DGDA registration, via MedEx).

Brand Manufacturer Strength Unit price ≈ USD Pack
Alkixen Lowest Everest Pharmaceuticals Ltd. 250 mg Capsule BDT 350 US$2.85 1 x 30: ৳ 10,500.00
Algrofin Genvio Pharma Ltd. 250 mg Capsule BDT 750 US$6.10 7 x 4: ৳ 21,000.00
Alkriz Beacon Pharmaceuticals PLC 250 mg Capsule BDT 750 US$6.10 7 x 4: ৳ 21,000.00
Crizona Ziska Pharmaceuticals Ltd. 250 mg Capsule BDT 750 US$6.10 3 x 10: ৳ 22,500.00
Crizonil Jenphar Bangladesh Ltd. 250 mg Capsule BDT 750 US$6.10 1 x 30: ৳ 22,500.00
Rizonib Drug International Ltd. 250 mg Capsule BDT 750 US$6.10 3 x 10: ৳ 22,500.00
Crizocent Incepta Pharmaceuticals Ltd. 250 mg Capsule BDT 1,500 US$12.21 3 x 4: ৳ 18,000.00

Source: MedEx Bangladesh drug registry (list prices of DGDA-registered brands). Unit prices move with pack size, pharmacy and exchange rate — reference only. Original registry page

Import and regulatory notes

Directorate General of Drug Administration (DGDA). Bangladesh is the reference market for this price guide: it is a least-developed-country WTO member with a patent exemption for pharmaceuticals until 2033, so local manufacturers legally produce on-patent molecules. Products are registered with the DGDA and carry a Bangladesh MRP; buying at pharmacy level usually means a per-strip or per-box price in BDT.

How to obtain it legally

  1. Obtain a prescription plus the diagnostic/genetic report from the treating physician (e.g. the target-mutation result).
  2. Confirm the exact brand and strength, and ask the supplier for the batch number, certificate of analysis (COA) and the manufacturer's GMP credentials.
  3. Clear the shipment through a DGDA-licensed importer or pharmacy; unregistered products go through the named-patient route.
  4. Check batch number, expiry and packaging on arrival, then follow the prescriber's monitoring schedule.

What adds to the price when you import

Availability in Southeast Asia

CountryStatusNotes
Bangladesh (regional supply hub)AvailableBeacon's export page lists Bangladesh-origin crizotinib as supplied to Nepal, Sri Lanka, Pakistan, Myanmar and Cambodia; at least seven domestic crizotinib brands are registered

Frequently asked questions

How much does crizotinib cost in Bangladesh?

There is no fixed public retail price for crizotinib in Bangladesh in the sources we track (most supply is hospital- or named-patient based). Use the Bangladesh list price as the benchmark: BDT 350–BDT 1,500 (US$2.85–US$12.21) per unit, about BDT 350–BDT 1,500 in BDT per unit and BDT 10,500–BDT 45,000 per 30-unit month, before freight, customs duty and distributor margin.

Can I legally import crizotinib into Bangladesh?

Yes, but only through the rules of the Directorate General of Drug Administration (DGDA): Bangladesh is the reference market for this price guide: it is a least-developed-country WTO member with a patent exemption for pharmaceuticals until 2033, so local manufacturers legally produce on-patent molecules. Products are registered with the DGDA and carry a Bangladesh MRP; buying at pharmacy level usually means a per-strip or per-box price in BDT. Prescription medicines must move on a valid prescription through a licensed importer, pharmacy or hospital; personal-use imports need a named-patient / compassionate-use authorisation.

Are Bangladeshi or Indian generics of crizotinib approved in Bangladesh?

We cannot confirm the registration status of every individual generic brand in Bangladesh. Directorate General of Drug Administration (DGDA) is the approving authority, and only products with a local product registration (or a special import authorisation) may be sold routinely. Ask your supplier for the local registration or import permit for the specific brand before you buy.

Why is the Bangladesh price a useful reference?

Bangladesh is a least-developed-country WTO member with a pharmaceutical patent exemption running to 2033, so local manufacturers can legally produce molecules that are still on patent elsewhere — and DGDA-registered list prices are public. That makes it the practical global floor price for on-patent targeted therapy and the benchmark used in import negotiations.

What is the availability situation for crizotinib in Bangladesh?

Bangladesh (regional supply hub): Available. Beacon's export page lists Bangladesh-origin crizotinib as supplied to Nepal, Sri Lanka, Pakistan, Myanmar and Cambodia; at least seven domestic crizotinib brands are registered

This molecule in other markets

Medical and legal notice

This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.

Need a verified quotation?

Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.

We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.